Mostrar el registro sencillo del ítem

AutorLange, Christoph
AutorAbubakar, Ibrahim
AutorAlffenaar, Jan-Willem C
AutorBothamley, Graham
AutorCaminero, Jose A
AutorCarvalho, Anna Cristina Calçada
AutorChang, Kwok-Chiu
AutorCodecasa, Luigi
AutorCorreia, Ana
AutorCrudu, Valeriu
AutorDavies, Peter
AutorDedicoat, Martin
AutorDrobniewski, Francis
AutorDuarte, Raquel
AutorEhlers, Cordula
AutorErkens, Connie
AutorGoletti, Delia
AutorGünther, Gunar
AutorIbraim, Elmira
AutorKampmann, Beate
AutorKuksa, Liga
AutorLange, Wiel de
Autorvan Leth, Frank
Autorvan Lunzen, Jan
AutorMatteelli, Alberto
AutorMenzies, Dick
AutorMonedero, Ignacio
AutorRichter, Elvira
AutorRüsch-Gerdes, Sabine
AutorSandgren, Andreas
AutorScardigli, Anna
AutorSkrahina, Alena
AutorTortoli, Enrico
AutorVolchenkov, Grigory
AutorWagner, Dirk
Autorvan der Werf, Marieke J
AutorWilliams, Bhanu
AutorYew, Wing-Wai
AutorZellweger, Jean-Pierre
AutorCirillo, Daniela Maria
Fecha de acceso2015-06-01T19:34:25Z
Fecha de disponibilización2015-06-01T19:34:25Z
Fecha de publicación2014
ReferenciaLANGE, Christoph et al. Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J , v.44, n.1, p.23–63, 2014.pt_BR
ISSN1399-3003pt_BR
URIhttps://www.arca.fiocruz.br/handle/icict/10621
Idiomaengpt_BR
EditorThe ERSpt_BR
Derechos de autorrestricted access
Palabras clave en PortuguésTuberculosept_BR
Palabras clave en PortuguésResistência a Medicamentospt_BR
Palabras clave en PortuguésEuropapt_BR
TítuloManagement of patients with multi-drug resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statementpt_BR
Tipo del documentoArticle
DOI10.1183/09031936.00188313pt_BR
Resumen en InglésThe emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.pt_BR
AfiliaciónGerman Center for Infection Diseases. Research Center Borstel. Medical Clinic. Division of Clinical Infectious Diseases. Borstel, Germany / University of Namibia, School of Medicine. Windhock, Namibia.pt_BR
AfiliaciónUniversity College of London. MRC Clinical Trials Unit. Research Dept of Infections and Population health. London, UK.pt_BR
AfiliaciónUniversity of Groningen. University Medical Center Groningen. Dept. of Clinical Pharmacy and Pharmacology. Groningen, The Netherlands.pt_BR
AfiliaciónHomerton University Hospital. London, UK.pt_BR
AfiliaciónUniversity Hospital of Gran Canaria " Dr. Negrin" . Dept. of Pneumology. Las Palmas de Gran Canaria, Spain / International Union against Tuberculosis and Lung Disease (The Union). Tuberculosis and HIV Dept., Multi-Drug-Resistant Tuberculosis Unit. Paris, France.pt_BR
AfiliaciónUniversity of Brescia. WHO Collaborating Centre for TB/HIV Co-infections. Clinic of Infectious and Tropical Disease, Brescia, Italy / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inovações em terapias, Ensino e Bioprodutos (LITEB). Rio de Janeiro, RJ, Brasil.pt_BR
AfiliaciónTuberculosis and Chest Service. Dept. of Health. Hong Kon, China.pt_BR
AfiliaciónNiguarda Ca`Granda Hospital. Villa Marelli Institute. Regional TB Reference Centre. Milan,Italy.pt_BR
AfiliaciónPortuguese Northern Health Administration. Public Health Dept. Porto, Portugal.pt_BR
AfiliaciónPhthisiopneumology Institute. Chisanu, Republic of Moldova.pt_BR
AfiliaciónLiverpool Heart and Chest Hospital. Liverpool, UK.pt_BR
AfiliaciónHeart of Enland Foundation Trust. BIrmingham, UK / University of Warwick. Coventry, UK.pt_BR
AfiliaciónPublic Health England National Mycobacterial Reference Laboratory. Imperial College. London, UK.pt_BR
AfiliaciónCentro Hospitalar de Vila Nova de Gaia / Espinho. Portuguese Reference Centre for M/XDR-TB / University of Porto. Institute of Public Health. Predictive Medicine and Public Health. Dept. of Clinical Epidemiology. Porto, Portugal.pt_BR
AfiliaciónTake That TB. Hamburg, Germany.pt_BR
AfiliaciónKNCV Tuberculosis Foundation. The Hague, The Netherlands.pt_BR
Afiliación" L`Spallanzani" National Institute for Infectious Diseases (INMI). Dept. of Epidemiology and Preclinical Research. Translational Research Unit. Rome, Italy.pt_BR
AfiliaciónGerman Center for Infection Diseases. Research Center Borstel. Medical Clinic. Division of Clinical Infectious Diseases. Borstel, Germany / University of Namibia, School of Medicine. Windhock, Namibia.pt_BR
AfiliaciónMarius Nasta Institute of Pulmonology. Bucharest, Romania.pt_BR
AfiliaciónImperial College. Dept. of Pediatrics. London, UK / MRC Unit. Vaccinology Theme. The Gambia.pt_BR
AfiliaciónRiga East University Hospital. Tuberculosis and Lung Disease center. Riga, Latvia.pt_BR
AfiliaciónUniversity Medical Center Groningen. Tuberculosis Center Beatrixoord. Groningen, The Netherlands.pt_BR
AfiliaciónUniversity of Amsterdam. Academic Medical Center. Dept. of Global Health. Amsterdam, The Netherlands / Amsterdam Institute of Global Health and Development. Amsterdam, The Netherlands.pt_BR
AfiliaciónUniversity Medical Center Hamburg. Infectious Diseases Unit. Hamburg, Germany.pt_BR
AfiliaciónUniversity of Brescia. WHO Collaborating Centre for TB/HIV Co-Infection. Clinic of Infectious and Tropical Diseases. Brescia, Italy.pt_BR
AfiliaciónMcGill University. Montreal Chest Institute. Montreal, Canada.pt_BR
AfiliaciónThe Union. Tuberculosis and HIV Dept. Multidrug-Resistant Tuberculosis Unit. Paris, France / Hospital Serveis Clinic. Barcelona, Spain.pt_BR
AfiliaciónResearch Center Borstel. National Reference Center for Mycobacteria. Borstel, Germany.pt_BR
AfiliaciónResearch Center Borstel. National Reference Center for Mycobacteria. Borstel, Germany.pt_BR
AfiliaciónEuropean Centre for Disease Prevention and Control (ECDC). Stockholm, Sweden.pt_BR
AfiliaciónThe Union. Tuberculosis and HIV Dept. Multidrug-Resistant Tuberculosis Unit. Paris, France.pt_BR
AfiliaciónRepublican Research and Practical Centre for Pulmonology and Tuberculosis. Minsk, Belarus.pt_BR
AfiliaciónSan Raffaele Scientific Institute. Emerging Bacterial Pathogens Unit. Milan, Italy.pt_BR
AfiliaciónCenter of Excekkence for TB Infection Control. Vladimir Regional TB Dispensary. Vladimir. Russia.pt_BR
AfiliaciónUniversity Medical Center Freiburg. Center for Infectious Diseases. Center for Chronic Immunodeficiency, Freiburg, Germany.pt_BR
AfiliaciónECDC. Stockhol, Sweden.pt_BR
AfiliaciónNorth West London Hospitals NHS Trust. Dept. of Paediatrics. London, UK.pt_BR
AfiliaciónThe Chinise University of Hong Kong. Stanley Ho Centre for Emerging Infectious Diseases. Hong Kong, China.pt_BR
AfiliaciónSwiss Ling Association. Berne, Switzerland.pt_BR
AfiliaciónSan Raffaele Scientific Institute. Emerging Bacterial Pathogens Unit. Milan, Italypt_BR
Palavras clave en InglêsTuberculosispt_BR
Palavras clave en InglêsDrug-resistantpt_BR
Palavras clave en InglêsEuropept_BR
Palavras clave en InglêsMultidrug-resistantpt_BR
xmlui.metadata.dc.subject.ods03 Saúde e Bem-Estar


Ficheros en el ítem

application/pdf
Nombre:
ana_carvalhoetal_IOC_2014.pdf
Tamaño:
1.389Mb
Formato:
application/
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem